Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Iafa Keydar

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Molecular Immunology|October 19, 2004
Humanization and epitope mapping of the H23 anti-MUC1 monoclonal antibody reveals a dual epitope specificityYariv Mazor, Iafa Keydar, Itai Benhar
Journal of Immunological Methods|March 6, 2007
Antibody internalization studied using a novel IgG binding toxin fusionYariv Mazor, Itay Barnea, Iafa Keydar, et al.
Cancer Letters|December 15, 2004
The angiogenic factors CXCL8 and VEGF in breast cancer: regulation by an array of pro-malignancy factorsElina Azenshtein, Tsipi Meshel, Sima Shina, et al.
Molecular Cancer|November 7, 2006
MUC1 gene overexpressed in breast cancer: structure and transcriptional activity of the MUC1 promoter and role of estrogen receptor alpha (ERalpha) in regulation of the MUC1 gene expressionJoseph Z Zaretsky, Itay Barnea, Yael Aylon, et al.
The Israel Medical Association Journal : IMAJ|November 29, 2002
Breast carcinoma: a report on the potential usage of the CC chemokine RANTES as a marker for a progressive diseaseNely Wigler, Sima Shina, Ofer Kaplan, et al.
Neoplasia (New York, N.Y.)|June 3, 2008
Human endogenous retrovirus (HERV-K) reverse transcriptase as a breast cancer prognostic markerMaya Golan, Amnon Hizi, James H Resau, et al.
Cancer Research|February 28, 2002
The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activityElina Azenshtein, Galia Luboshits, Sima Shina, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2006
The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patientsNeora Yaal-Hahoshen, Sima Shina, Leonor Leider-Trejo, et al.
Cancer Research|November 3, 2004
A unique mucin immunoenhancing peptide with antitumor propertiesLynn M Herbert, Joseph F Grosso, Mantley Dorsey, et al.
Cytokine|September 16, 2008
Concomitant expression of the chemokines RANTES and MCP-1 in human breast cancer: a basis for tumor-promoting interactionsGali Soria, Neora Yaal-Hahoshen, Elina Azenshtein, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Molecular Immunology|October 19, 2004
Humanization and epitope mapping of the H23 anti-MUC1 monoclonal antibody reveals a dual epitope specificityYariv Mazor, Iafa Keydar, Itai Benhar
Journal of Immunological Methods|March 6, 2007
Antibody internalization studied using a novel IgG binding toxin fusionYariv Mazor, Itay Barnea, Iafa Keydar, et al.
Cancer Letters|December 15, 2004
The angiogenic factors CXCL8 and VEGF in breast cancer: regulation by an array of pro-malignancy factorsElina Azenshtein, Tsipi Meshel, Sima Shina, et al.
Molecular Cancer|November 7, 2006
MUC1 gene overexpressed in breast cancer: structure and transcriptional activity of the MUC1 promoter and role of estrogen receptor alpha (ERalpha) in regulation of the MUC1 gene expressionJoseph Z Zaretsky, Itay Barnea, Yael Aylon, et al.
The Israel Medical Association Journal : IMAJ|November 29, 2002
Breast carcinoma: a report on the potential usage of the CC chemokine RANTES as a marker for a progressive diseaseNely Wigler, Sima Shina, Ofer Kaplan, et al.
Neoplasia (New York, N.Y.)|June 3, 2008
Human endogenous retrovirus (HERV-K) reverse transcriptase as a breast cancer prognostic markerMaya Golan, Amnon Hizi, James H Resau, et al.
Cancer Research|February 28, 2002
The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activityElina Azenshtein, Galia Luboshits, Sima Shina, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2006
The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patientsNeora Yaal-Hahoshen, Sima Shina, Leonor Leider-Trejo, et al.
Cancer Research|November 3, 2004
A unique mucin immunoenhancing peptide with antitumor propertiesLynn M Herbert, Joseph F Grosso, Mantley Dorsey, et al.
Cytokine|September 16, 2008
Concomitant expression of the chemokines RANTES and MCP-1 in human breast cancer: a basis for tumor-promoting interactionsGali Soria, Neora Yaal-Hahoshen, Elina Azenshtein, et al.
Pageof 2